KRAS and endometrial cancer: KRAS mutations were found in 17.9% of the cases, with high frequency of point mutations in exon 2 (G12A, G12C, G12D and G13D), validated in 264 endometrial cancer patients (14,7%; [14]) and also in line with previous studies (18%; [30]).